https://www.selleckchem.com/pr....oducts/rxdx-106-cep-
523, P= 0.2171). No clot-related sequelae occurred in any patient. Three hemorrhages occurred, all in patients not on anticoagulants. We found no increased risk of complications in patients routinely on anticlotting medication undergoing DBS lead placement. We show that our protocol was successful in balancing increased risks of bleeding and of thromboembolic events in this patient group. We found no increased risk of complications in patients routinely on anticlotting medication undergoing DBS lead placement. We show that ou
Like
Comment
Share
